Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has released a shareholder update outlining its three innovation programs and strategic M&A initiatives. The update notes that subsidiary Pearsanta submitted a bid to acquire substantially all assets of Lucira Health Inc., including Lucira Connect and FDA-approved at-home combination COVID-19 and flu tests. The company was chosen as a backup bidder. Despite an objection filed by Aditxt noting issues related to fairness and good faith, Pearsanta remains the backup bidder. Earlier this month, Aditxt formed a wholly owned subsidiary, Adivir Inc., focused on the company’s therapeutics and antimicrobial program. The company continues to consider a potential transaction with Cellvera, a company focused on discovering, developing and commercializing antimicrobial therapies across a broad spectrum of infectious diseases. Aditxt continues to move forward with its human clinical trials in Germany, studying Adimune. The studies will focus on psoriasis, with the objective being to add human trials in the United States later this year. “Aditxt’s vision is dedicated to a new era of precision medicine through individual immune monitoring and modulation,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “We are laser-focused on advancing each of our innovation programs toward commercialization. Adimune’s initiation of ADI-100 manufacturing is measurable progress of Adimune toward our 2023 strategic goals.”
To view the full press release, visit https://ibn.fm/66JW9
About Aditxt Inc.
Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. The company’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders that inform and inspire. Aditxt’s diverse innovation portfolio includes Adimune Inc.(TM), developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir Inc.(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta Inc.(TM), which offers personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
